NASDAQ:TYRA Tyra Biosciences (TYRA) Stock Price, News & Analysis → Biden to Launch “FedNOW” [Move Your Money Now] (From Priority Gold) (Ad) Free TYRA Stock Alerts $18.53 +0.24 (+1.31%) (As of 05/2/2024 ET) Add Compare Share Share Today's Range$17.82▼$18.5950-Day Range$14.45▼$20.0052-Week Range$10.38▼$20.67Volume105,103 shsAverage Volume126,615 shsMarket Capitalization$973.20 millionP/E RatioN/ADividend YieldN/APrice Target$22.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Tyra Biosciences alerts: Email Address Tyra Biosciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside18.7% Upside$22.00 Price TargetShort InterestBearish13.78% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$298,165 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($1.94) to ($2.41) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.43 out of 5 starsMedical Sector862nd out of 907 stocksPharmaceutical Preparations Industry396th out of 414 stocks 2.3 Analyst's Opinion Consensus RatingTyra Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageTyra Biosciences has only been the subject of 2 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted13.78% of the float of Tyra Biosciences has been sold short.Short Interest Ratio / Days to CoverTyra Biosciences has a short interest ratio ("days to cover") of 23.4, which indicates bearish sentiment.Change versus previous monthShort interest in Tyra Biosciences has recently increased by 15.55%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldTyra Biosciences does not currently pay a dividend.Dividend GrowthTyra Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TYRA. Previous Next 1.3 News and Social Media Coverage News SentimentTyra Biosciences has a news sentiment score of 0.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Tyra Biosciences this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for TYRA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Tyra Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $298,165.00 in company stock.Percentage Held by Insiders15.40% of the stock of Tyra Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions84.14% of the stock of Tyra Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Tyra Biosciences are expected to decrease in the coming year, from ($1.94) to ($2.41) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tyra Biosciences is -11.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tyra Biosciences is -11.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTyra Biosciences has a P/B Ratio of 3.91. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad AltimetryUrgent Nvidia WarningCould Steve Job's 'Final Prophecy' Make You Rich? Just before he died, Steve Jobs issued a "Final Prophecy" that's now coming true... and making some people rich. In one recent 90-day stretch, 50 companies related to Jobs' "Final Prophecy" soared by 100% or more. What was Steve Jobs' last big prediction, and how can you get in on it? Professor Joel Litman explains everything... including the surprising group of stocks moving higher, and his No. 1 favorite stock in this space.Click here to access… About Tyra Biosciences Stock (NASDAQ:TYRA)Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.Read More TYRA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TYRA Stock News HeadlinesMarch 26, 2024 | markets.businessinsider.comTyra Bioscience Poised for Growth: Buy Rating Affirmed Amid Promising Clinical Trials and Strategic Drug DevelopmentMarch 19, 2024 | msn.comTYRA Stock Earnings: Tyra Biosciences Misses EPS for Q4 2023May 3, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.March 19, 2024 | finance.yahoo.comTyra Biosciences Inc (TYRA) Reports Increased R&D Investments Amid Pipeline ProgressMarch 19, 2024 | msn.comTyra Biosciences files to sell 15.37M shares of common stock for holdersMarch 19, 2024 | finance.yahoo.comTyra Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and HighlightsMarch 6, 2024 | finance.yahoo.comInsider Sell: Tyra Biosciences Inc (TYRA) COO Daniel Bensen Sells 9,152 SharesMarch 1, 2024 | finance.yahoo.comInsider Sell: Tyra Biosciences Inc (TYRA) COO Daniel Bensen Sells 8,644 SharesMay 3, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.February 27, 2024 | prnewswire.comTyra Biosciences to Present at Upcoming Investor ConferencesFebruary 24, 2024 | msn.comTyra Biosciences (TYRA) Price Target Increased by 5.41% to 23.87February 17, 2024 | finance.yahoo.comTYRA Mar 2024 20.000 callFebruary 17, 2024 | finance.yahoo.comTYRA Mar 2024 20.000 putFebruary 7, 2024 | finance.yahoo.comTyra Biosciences to Present at Oppenheimer's 34th Annual Healthcare Life Sciences ConferenceFebruary 7, 2024 | finance.yahoo.comPresident and CEO Todd Harris Sells 100,000 Shares of Tyra Biosciences Inc (TYRA)February 6, 2024 | msn.comTyra Bioscience Announces New Purchase AgreementFebruary 6, 2024 | msn.comTyra Bioscience Secures $200M for Clinical Drug DevelopmentFebruary 2, 2024 | nasdaq.comTyra Biosciences Climbs 23% After Announcing $200 Mln Private PlacementFebruary 2, 2024 | marketwatch.comTyra Shares Jump After $200 Million Private Placement FundingFebruary 2, 2024 | msn.comTyra Biosciences spikes on $200M private financingFebruary 2, 2024 | finance.yahoo.comTyra Biosciences, Inc. Announces $200 Million Private Placement FinancingFebruary 1, 2024 | markets.businessinsider.comTyra : FDA Grants Rare Pediatric Disease Designation To TYRA-300 For Achondroplasia TreatmentFebruary 1, 2024 | marketwatch.comTyra Biosciences Gets Rare Pediatric Disease Designation For Achondroplasia TherapyFebruary 1, 2024 | finance.yahoo.comTyra Biosciences Receives FDA Rare Pediatric Disease Designation for TYRA-300 for the Treatment of AchondroplasiaDecember 29, 2023 | realmoney.thestreet.comWedbush stays Outperform on Tyra Biosciences after pipeline updatesDecember 22, 2023 | finance.yahoo.comTyra Biosciences Doses First Patient with TYRA-200 and Provides Positive Updates on TYRA-300December 16, 2023 | health.usnews.comTyra S. CarterSee More Headlines Receive TYRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tyra Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/19/2024Today5/03/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:TYRA CUSIPN/A CIK1863127 Webwww.tyra.bio Phone619-728-4760FaxN/AEmployees49Year FoundedN/APrice Target and Rating Average Stock Price Target$22.00 High Stock Price Target$28.00 Low Stock Price Target$15.00 Potential Upside/Downside+18.7%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.61) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-69,130,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-30.26% Return on Assets-28.53% Debt Debt-to-Equity RatioN/A Current Ratio13.81 Quick Ratio13.80 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.74 per share Price / Book3.91Miscellaneous Outstanding Shares52,520,000Free Float44,435,000Market Cap$973.20 million OptionableOptionable Beta1.08 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. Todd Harris Ph.D. (Age 45)Co-Founder, President, CEO, Secretary, Treasurer & Director Comp: $903.33kMr. Daniel Bensen (Age 48)Co-Founder & COO Comp: $630.8kMr. Ali D. Fawaz J.D.General Counsel & SecretaryMr. Alan Fuhrman (Age 67)Chief Financial Officer Dr. Robert L. Hudkins Ph.D. (Age 68)Chief Technology Officer Dr. Ronald V. Swanson Ph.D. (Age 60)Chief Scientific Officer Comp: $536.19kMs. Sarah HonigVice President of Corporate Development & StrategyDr. Hiroomi Tada M.D. (Age 60)Ph.D., Chief Medical Officer Comp: $519.65kDr. Piyush R. Patel Ph.D. (Age 58)Chief Development Officer Amy ConradInvestor ContactMore ExecutivesKey CompetitorsCentessa PharmaceuticalsNASDAQ:CNTAMacroGenicsNASDAQ:MGNXABIVAX Société AnonymeNASDAQ:ABVXALX OncologyNASDAQ:ALXOOPKO HealthNASDAQ:OPKView All CompetitorsInsiders & InstitutionsFishman Jay A Ltd. MIBought 15,000 shares on 4/23/2024Ownership: 0.029%Daniel BensenSold 200 sharesTotal: $4,000.00 ($20.00/share)Daniel BensenSold 1,733 sharesTotal: $34,815.97 ($20.09/share)Wellington Management Group LLPBought 8,324 shares on 3/5/2024Ownership: 0.238%Daniel BensenSold 2,050 sharesTotal: $41,000.00 ($20.00/share)View All Insider TransactionsView All Institutional Transactions TYRA Stock Analysis - Frequently Asked Questions Should I buy or sell Tyra Biosciences stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tyra Biosciences in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" TYRA shares. View TYRA analyst ratings or view top-rated stocks. What is Tyra Biosciences' stock price target for 2024? 3 analysts have issued 12-month target prices for Tyra Biosciences' stock. Their TYRA share price targets range from $15.00 to $28.00. On average, they anticipate the company's share price to reach $22.00 in the next twelve months. This suggests a possible upside of 18.7% from the stock's current price. View analysts price targets for TYRA or view top-rated stocks among Wall Street analysts. How have TYRA shares performed in 2024? Tyra Biosciences' stock was trading at $13.85 on January 1st, 2024. Since then, TYRA stock has increased by 33.8% and is now trading at $18.53. View the best growth stocks for 2024 here. How were Tyra Biosciences' earnings last quarter? Tyra Biosciences, Inc. (NASDAQ:TYRA) posted its quarterly earnings data on Tuesday, March, 19th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.48) by $0.05. When did Tyra Biosciences IPO? Tyra Biosciences (TYRA) raised $100 million in an initial public offering (IPO) on Wednesday, September 15th 2021. The company issued 6,700,000 shares at $14.00-$16.00 per share. Who are Tyra Biosciences' major shareholders? Tyra Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include Fishman Jay A Ltd. MI (0.03%). Insiders that own company stock include Boxer Capital, Llc, Daniel Bensen, Mva Investors, Llc and Todd Harris. View institutional ownership trends. How do I buy shares of Tyra Biosciences? Shares of TYRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TYRA) was last updated on 5/3/2024 by MarketBeat.com Staff From Our PartnersThe AI stock to buy right nowStockEarningsCould Your Accounts Be Frozen?Allegiance GoldUrgent Nvidia WarningAltimetryThe A.I. story nobody is telling you (Read ASAP)TradeSmith$5,000 Gold?Stansberry ResearchBitcoin Rockets To Record High But Buy THIS InsteadParadigm PressBill Gates is all about this tiny $2 stockTimothy SykesTruth about Trump you’ve never heardPorter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tyra Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
